EyePoint Pharmaceuticals Reports 91% Revenue Decline and Increased Losses in Q3 2025

EyePoint Pharmaceuticals, Inc. reported a significant decline in financial performance for the third quarter and the first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company generated total revenues of $966,000, a decrease of 91% compared to $10.5 million in the same period of 2024. The nine-month revenue figures also reflected a slight decline, totaling $30.8 million, down from $31.7 million year-over-year. The substantial drop in revenue was primarily attributed to a 98% decrease in license and collaboration agreement revenue, which fell to $150,000 from $9.6 million, largely due to the recognition of deferred revenue related to the licensing of YUTIQ® product rights.

The company's operating expenses increased significantly, totaling $63.0 million for the third quarter, up 46% from $43.3 million in the prior year. This rise was driven by a 62% increase in research and development expenses, which reached $47.8 million, reflecting ongoing investments in the Phase 3 clinical trials for its lead product candidate, DURAVYU™. The net loss for the third quarter was $59.7 million, compared to a loss of $29.4 million in the same quarter of 2024, marking a 103% increase in losses. The net loss per share also widened to $(0.85) from $(0.54).

In terms of operational developments, EyePoint completed enrollment in two pivotal Phase 3 trials for DURAVYU™ in wet age-related macular degeneration (AMD) in mid-2025, with data readouts expected in mid-2026. The company also reported a strategic shift in its licensing agreements, including the termination of the ANI commercial supply agreement, which contributed to the decline in product sales. The company’s cash and cash equivalents, along with marketable securities, totaled $204 million as of September 30, 2025, down from $418.5 million at the end of 2024, indicating a need for continued capital management.

Looking ahead, EyePoint anticipates that its existing cash reserves, combined with approximately $162.1 million raised from an equity financing in October 2025, will support its operations into the fourth quarter of 2027. However, the company acknowledges the ongoing challenges of funding its research and development activities, particularly as it continues to incur significant operating losses. The management remains focused on advancing its clinical programs and exploring additional funding opportunities to sustain its operations and support future growth.